Trial Profile

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XMT 1592 (Primary)
Indications Adenocarcinoma; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; First in man; Proof of concept
Sponsors Mersana Therapeutics

Most Recent Events

05 Jan 2024 According to a Mersana Therapeutics media release, results will published in the in the first half of 2024.
03 Oct 2023 Status changed from active, no longer recruiting to discontinued.
23 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com